Boston Scientific Corporation (NYSE:BSX) has announced a delay in completing its merger with Axonics, as a result of a request for additional information by the U.S. Federal Trade Commission (FTC).

The request, which the companies received on April 3, 2024, pauses the merger's progress while extending the waiting period until 30 days after both Boston Scientific and Axonics have complied.

This development pushes the anticipated completion date of the merger to the second half of 2024, contingent on meeting all regulatory requirements and customary closing conditions.

In response to the FTC's inquiry, both Boston Scientific and Axonics are prepared to cooperate fully, with intentions to promptly comply with the request for additional information.